Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric Crohn's disease study of guselkumab
2021-006282-37Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of guselkumab in Crohn's disease (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical remission. Started Nov 2022; status: active.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2021-006282-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006282-37.